Literature DB >> 23983572

Apoptotic activities in soft tissue sarcoma: immunohistochemical study and their association with tumour characteristics.

Thin Thin Win1, Yusri Yusuf, Hasnan Jaafar.   

Abstract

BACKGROUND: Many studies on the role of apoptosis in cancer development and management have been undertaken. Apoptotic activity depends partly on the balance between anti-apoptotic (Bcl-2) and pro-apoptotic (Bax) activities. This study compared Bcl-2 and Bax expression in the tumour cells and endothelial cells of tumour blood vessels in soft tissue sarcoma, and examined the association of these with tumour characteristics.
METHODS: A cross sectional (retrospective) study was conducted on 101 cases of various types of soft tissue sarcoma tumour cells and endothelial cells of tumour blood vessels. The immunohistochemical expressions of Bcl-2 and Bax were compared by correlating them according to site, size, depth, tumour margin, lymph node involvement, and histological type.
RESULTS: Higher Bax than Bcl-2 expression in tumour cells was observed, although the difference was not statistically significant. There was a significant direct association between Bcl-2 and Bax in tumour cells with endothelial cells. Among tumour characteristics, the only significant correlation was that of the Bcl-2 expression in tumour cells with tumour histological subtypes (synovial sarcoma and leiomyosarcoma).
CONCLUSION: The findings in this study support the role of endothelial cells in the survival and regression of tumour cells in tumour genesis. Therefore, inhibition of endothelial cell survival and activation, or induction of tumour cell apoptosis offers a promising prospect for tumour management.

Entities:  

Keywords:  Apoptosis; Bax; Bcl-2; soft tissue sarcoma

Year:  2013        PMID: 23983572      PMCID: PMC3743994     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  19 in total

1.  Apoptosis during breast carcinoma progression.

Authors:  M Vakkala; K Lähteenmäki; H Raunio; P Pääkkö; Y Soini
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  The immunoexpression of bcl-2 and p53 in Kaposi's sarcoma.

Authors:  M A Dada; R Chetty; S C Biddolph; J W Schneider; K C Gatter
Journal:  Histopathology       Date:  1996-08       Impact factor: 5.087

3.  Synergy between tumor immunotherapy and antiangiogenic therapy.

Authors:  Smita Nair; David Boczkowski; Benjamin Moeller; Mark Dewhirst; Johannes Vieweg; Eli Gilboa
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis.

Authors:  H Nakanishi; M Ohsawa; N Naka; A Uchida; T Ochi; K Aozasa
Journal:  Oncology       Date:  1997 May-Jun       Impact factor: 2.935

5.  Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas.

Authors:  S Kawauchi; T Fukuda; M Tsuneyoshi
Journal:  Oncol Rep       Date:  1999 Sep-Oct       Impact factor: 3.906

Review 6.  Apoptosis and cancer chemotherapy.

Authors:  G Makin; J A Hickman
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

7.  Apoptosis and expression of its regulatory proteins in soft tissue sarcomas.

Authors:  Tomoyuki Dan'ura; Akira Kawai; Yuki Morimoto; Noriko Naito; Aki Yoshida; Hajime Inoue
Journal:  Cancer Lett       Date:  2002-04-25       Impact factor: 8.679

8.  Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis.

Authors:  A Shilkaitis; J Graves; R R Mehta; L Hu; M You; R Lubet; V Steele; G Kelloff; K Christov
Journal:  Cell Growth Differ       Date:  2000-08

9.  Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.

Authors:  E Yang; J Zha; J Jockel; L H Boise; C B Thompson; S J Korsmeyer
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

10.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more
  1 in total

1.  Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.

Authors:  Marieke A de Graaff; Marije A J de Rooij; Brendy E W M van den Akker; Hans Gelderblom; Fréderic Chibon; Jean-Michel Coindre; Adrian Marino-Enriquez; Jonathan A Fletcher; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Br J Cancer       Date:  2016-05-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.